The pursuit for CJC-1295 in Haar reliably produces the same conclusion: research peptides are distributed through specialist online vendors, not local retail. This concentration of supply in online vendors is ultimately a quality advantage — top vendors compete on lab-verified purity in ways local stores never could. What genuinely separates top CJC-1295 vendors is full COA coverage: HPLC for purity, mass spec for molecular identity verification, and endotoxin testing for contamination assurance. This guide gives Haar researchers the methodology to verify sourcing options methodically and source verified-quality CJC-1295 with confidence.
How CJC-1295 Works — Mechanisms & Research
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Haar comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Source CJC-1295 — Vendor Guide
Quality CJC-1295 sourcing begins with a simple filter: does this vendor publish batch-specific COAs proactively? Those who make this data freely available are operating transparently. Endotoxin testing in the COA is critical for any injectable research use — endotoxins from bacterial cell wall components can trigger serious immune reactions even at minute levels. For Haar researchers evaluating unfamiliar vendors: a small initial order to verify quality before scaling up your order is standard practice in the community. Keep lyophilised CJC-1295 at −20°C until ready to use; reconstitute only the volume needed for upcoming use and return unused portion to the freezer.
Order CJC-1295 — ships to Haar
COA-verified · International tracking · Research grade
Research compound status for CJC-1295 means safety data comes from animal studies, in-vitro work, and limited human observations — rather than the controlled trials that generate pharmaceutical safety profiles. Lyophilised CJC-1295 should be stored frozen (−20°C) immediately upon receipt; repeated freeze-thaw cycles of reconstituted material should be avoided by aliquoting into single-use portions. Verify the endotoxin level in your CJC-1295 batch COA before any protocol involving administration — look for results stated as EU/mg and verify they are within the acceptable range for your research context. Researchers running multi-compound protocols with CJC-1295 should examine published studies for potential interaction data before running stacked compound experiments.
Frequently Asked Questions
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
